CN1236779A - Process for preparing bismuth ranitidine-citrate - Google Patents
Process for preparing bismuth ranitidine-citrate Download PDFInfo
- Publication number
- CN1236779A CN1236779A CN 99114171 CN99114171A CN1236779A CN 1236779 A CN1236779 A CN 1236779A CN 99114171 CN99114171 CN 99114171 CN 99114171 A CN99114171 A CN 99114171A CN 1236779 A CN1236779 A CN 1236779A
- Authority
- CN
- China
- Prior art keywords
- citrate
- ranitidine
- bismuth
- reaction
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052797 bismuth Inorganic materials 0.000 title claims abstract description 36
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000006243 chemical reaction Methods 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000003756 stirring Methods 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims description 23
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 9
- 230000035484 reaction time Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 3
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 229960000620 ranitidine Drugs 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 abstract 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 239000000047 product Substances 0.000 description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- XAUTYMZTJWXZHZ-IGUOPLJTSA-K bismuth;(e)-1-n'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-n-methyl-2-nitroethene-1,1-diamine;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 XAUTYMZTJWXZHZ-IGUOPLJTSA-K 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 229960004696 ranitidine bismuth citrate Drugs 0.000 description 3
- 238000002411 thermogravimetry Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QGWDKKHSDXWPET-UHFFFAOYSA-E pentabismuth;oxygen(2-);nonahydroxide;tetranitrate Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[O-2].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O QGWDKKHSDXWPET-UHFFFAOYSA-E 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
Abstract
A process for preparing bismuth ranitidine citrate, a heterocyclic compound double-salt as medicine for curing diseases in digestive tract system, includes such technological steps as dissolving ranitidine base in alcohol while stirring, adding bismuth citrate while stirring, reaction of ranitidine base with bismuth citrate at 0-35 deg.C under ultrasonic catalyzing for 0.5-10 hr while stirring, and separating out bismuth ranitidine citrate. Its advantages are high purity and output rate of product and short reaction period.
Description
The present invention relates to a kind of heterogeneous ring compound double salt, this heterogeneous ring compound contains pentatomic ring, this pentatomic ring contains a Sauerstoffatom as only ring hetero atom.
Citric Acid claims citric acid again.Ranitidine bismuth citrate is made by Ranitidine HCL and bismuth citrate reaction, is the medicine of class treatment gi system disease.Its chemical formula is C
13H
22N
4O
3SC
6H
5BiO
7, molecular weight is 712.48, formal name used at school is the N-[2-[5-[(dimethylamino) and methyl]-2-furyl methyl sulfo-] ethyl]-N '-methyl-2-nitro-1,1-ethylene diamine 2-hydroxyl-1,2,3-tricarballylic acid bismuth, its structural formula is as follows:
The method for preparing the Ranitidine HCL bismuth citrate that Chinese patent CN1022626C provides is, with water is solvent, following 90～95 ℃ of the temperature that raises, Ranitidine HCL and bismuth citrate are reacted to system are neutral, obtain target compound through separation---have the ranitidine bismuth citrate double salt of 0.48 or 0.34 crystal water.Because at high temperature, the easy oxidation of Ranitidine HCL and ranitidine bismuth citrate, so the purity of the finished product of this method gained is relatively poor, chromatogram checks that impurity is more, thereby gives the refining difficulty of bringing of finished product.Chinese patent application CN1156143A improves aforesaid method.It changes solvent Diluted Alcohol into and prolongs the reaction times to 20～and 30 hours and reaction is carried out at normal temperatures, the target compound that obtains after the separation is the bismuth citrate ranitidine that has two crystal water.Though this method reduced reactant and product decomposition, improved the purity of product, it is more that the reaction times is prolonged, yield is lower.
The objective of the invention is, the preparation method of the bismuth ranitidine-citrate that a kind of products therefrom purity is higher, yield is also higher, the reaction times relatively lacks is provided.
The technical scheme that realizes the object of the invention is, under agitation, the Ranitidine HCL base is joined make it in the solvent Diluted Alcohol dissolving, continue to stir and add bismuth citrate down, and Ranitidine HCL base and bismuth citrate are reacted, temperature of reaction is 0～35 ℃, reaction time is carried out the ultrasonic wave catalytic treatment to material to be made and reacts completely in 0.5～10 hour, isolated the bismuth ranitidine-citrate that is generated then from material.
The temperature of above-mentioned reaction is room temperature, can is 0～35 ℃ that preferred temperature is 18～28 ℃.The preferred reaction time of above-mentioned reaction is 1～8 hour, and the further preferred time is 2.5～4 hours.The concentration of the used Diluted Alcohol of above-mentioned reaction is 5～20%, and used ultrasonic frequency is to make material produce the frequency of resonance.The used ultrasonic frequency of above-mentioned reaction is 30～50KHZ.
The above-mentioned method of isolating the bismuth ranitidine-citrate that is generated from material is, with the material filtering after reacting completely, under violent stirring, add dewatering agent in the filtrate, make filtrate separate out throw out, after throw out filtration, drying, promptly get bismuth ranitidine-citrate.Violent stirring is that agitator speed is the stirring that per minute 200～350 changes.
The bismuth ranitidine-citrate of above-mentioned reaction gained is the double salt that contains a crystal water, and its chemical formula is C
13H
22N
4O
3S1.1C
6H
5BiO
70.3C
2H
5OHH
2O.
The present invention has positive effect: (1) is by the finished product of gained of the present invention, owing to be at room temperature to form through ultrasonic wave catalysis accelerated reaction, promptly at room temperature utilize ultrasonic wave to produce resonance effect, short-period shockwave, make between the solid-liquid two-phase to produce fast, contact fully and material transfer, reactant just can fast and effeciently be reacted under the condition of room temperature.We invention compares with CN1022626C that then temperature of reaction is lower, with CN1156143A then the reaction times shorter, thereby avoided the oxidation stain problem of Ranitidine HCL base and bismuth ranitidine-citrate, make the refining comparatively convenient of finished product.(2) the present invention is action solvent with the Diluted Alcohol, and Ranitidine HCL is fully dissolved, and obtains the solution of homogeneous, helps reacting with bismuth citrate.(3) to isolate the method that bismuth ranitidine-citrate adopted that is generated from material be " cold-treating process " in the present invention, avoided product because of problems such as the color and luster intensifications of being heated, improved the quality of finished product.(4) the prepared bismuth ranitidine-citrate of the present invention is the off-white color finished product, detect through high pressure liquid chromatography (HPLC), foreign matter content＜2%, yield is 65.5～93.6%, and the yield of the embodiment that feeds intake with the solid Ranitidine HCL equally among CN1022626C and the CN1156143A then is respectively 53.5% and 47.7%.(5) finished product that makes of present method through ultimate analysis, thermogravimetric analysis (TG), infrared absorption spectrum (IR), ultra-violet absorption spectrum (UV), proton nmr spectra (' HNMR), carbon-13 nmr spectra (
13CNMR), mass spectrum (MS), powder x-ray diffraction prove, this finished product is a kind of new chemical entities, be essentially different on physico-chemical property with the mixture of Ranitidine HCL and bismuth citrate (seeing Table 1), calculate that by one embodiment of the present of invention the chemical formula that draws its finished product is C
13H
22N
4O
3S1.1C
6H
5BiO
70.3C
2H
5OHH
2O.
Table 1 physico-chemical property comparison sheet
Bismuth ranitidine-citrate Ranitidine HCL base and bismuth citrate
Mixture (1: 1 mol ratio) fusing point (mP)＞150 ℃ (decomposition)＜74 ℃ water-soluble (clarification) soluble in water suspension
Below in conjunction with embodiment the present invention is further described.
Embodiment 1,
(1) preparation bismuth citrate (the molten method of sxemiquantitative ammonia).Citric Acid 100.8 grams (0.48 mole) are dissolved in 240 ml distilled waters, add Vikaline 70.2 grams (0.240 mole of bismuth-containing) of porphyrize, heat with boiling water, stirring reaction 1～2 hour, peek is dripped reaction solution and is splashed in 10 milliliters of ammoniacal liquor, and solution is clear state, and reaction finishes.Reaction equation is as follows:
Reaction solution is cooled to room temperature, and suction filtration, washing leaching cake be not to having Citric Acid and nitrate ion, and it is dry under 40 ℃ to put into baking oven after draining, and white powder solid 98.4 grams that get bismuth citrate content＞98% are stand-by.
(2) preparation Ranitidine HCL base.Ranitidine hydrochloride 200 gram is added in 300 ml waters, stirs and add saturated sodium bicarbonate solution down and react for 1100 milliliters, generate the Ranitidine HCL base.Reaction equation is as follows:
Extract with 300 milliliters of trichloromethane gradation then, extracting solution under reduced pressure concentrated go 2/3, then 600 milliliters of ethyl acetate are added crystallisation by cooling, filter, vacuum-drying, the off-white color or the light yellow crystalline powder solid Ranitidine HCL base that promptly get fusing point (mP) and be 67～70 ℃ are stand-by.
(3) preparation bismuth ranitidine-citrate.
It is that KQ-50B type, power are that 50 watts, operating frequency are the ultrasonoscope of being made by city of Kunshan's ultrasonic instrument factory of 40KHz that ultrasonoscope is selected model for use.The ultrasonic emitting head of this ultrasonoscope is arranged on the below of the sonication chamber housing that opening makes progress, and emitting head is aimed at sonication chamber.Put into tap water in the sonication chamber housing, in the tap water in the bottom immersion sonication chamber housing of three-necked flask, adding 70 ml concns are 15% solution in three-necked flask.Under agitation will mix with Diluted Alcohol solution in above-mentioned Ranitidine HCL base 33.0 gram (0.105 mole) the adding three-necked flasks and dissolve, add above-mentioned bismuth citrate 30.0 grams (0.0750 mole) again, stir, with reactor (three-necked flask) reaction 1 hour under 18 ℃ temperature and action of ultrasonic waves, obtain faint yellow reaction solution.Reaction equation is as follows:
The unreacted bismuth citrate of filtering, (per minute 300 changes) adds 500 milliliters of ethanol in the filtrate under violent stirring, produces the off-white color solid, and suction filtration with the washing with alcohol filter cake, is drained, and vacuum-drying gets off-white color solid 35 grams.Detect through the volumetric determination method, the percentage composition that records bismuth is 29.31%.Detect through high pressure liquid chromatography (HPLC), foreign matter content is 0.5%.Calculating yield is 65.5%.
Ultimate analysis: C% H% N%
Measured value 30.54 3.87 7.12
Calculated value 30.94 4.02 7.14.
Embodiment 2,
All the other are identical with embodiment 1, and difference is, during the preparation bismuth ranitidine-citrate, be 25 ℃ in temperature, reaction 3.5 hours under hyperacoustic catalysis, filter, faint yellow filtrate, under violent stirring (per minute 350 changes), 500 milliliters of ethanol are added in the filtrate, produce the off-white color solid, suction filtration, with the washing with alcohol filter cake, drain, vacuum-drying gets off-white color solid 48 grams.Detect through the volumetric determination method, the percentage composition that records bismuth is 29.35%.Detect through high pressure liquid chromatography (HPLC), foreign matter content is 0.8%.Calculating yield is 90.0%.
Ultimate analysis C% H% N%
Measured value 30.59 3.80 7.29
Calculated value 30.94 4.02 7.14.
Embodiment 3,
All the other are identical with embodiment 1, and difference is, during the preparation bismuth ranitidine-citrate, be 28 ℃ in temperature, reaction 8 hours under hyperacoustic catalysis, filter, faint yellow filtrate, under violent stirring (per minute 250 changes), 500 milliliters of ethanol are added in the filtrate, produce the off-white color solid, suction filtration, with the washing with alcohol filter cake, drain, vacuum-drying gets off-white color solid 50 grams.Detect through the volumetric determination method, the percentage composition that records bismuth is 29.25%.Detect through high pressure liquid chromatography (HPLC), foreign matter content is 1.2%.Calculating yield is 93.6%.
Ultimate analysis C% H% N%
Measured value 30.55 3.68 7.29
Calculated value 30.94 4.02 7.14.
This preparation method product through ultimate analysis, thermogravimetric analysis and ' the HNMR actual measurement, resolve.The second alcohol and water that this product loses from 40.0 ℃ to 60.3 ℃ is 4.06% of a gross weight, and deduction is by behind ' 0.3 mole the ethanol that HNMR records, and calculating dehydration is 2.30%, and promptly this product is moisture 2.3%, is equivalent to 1.00 mole of water.The binding analysis result, the chemical formula of releasing this product bismuth ranitidine-citrate is C
13H
22N
4O
3S1.1C
6H
5BiO
70.3C
2H
5OHH
2O.
Claims (10)
1, a kind of method by Ranitidine HCL and bismuth citrate prepared in reaction bismuth ranitidine-citrate, it is characterized in that, under agitation, the Ranitidine HCL base is joined make it in the solvent Diluted Alcohol dissolving, continue to stir and add bismuth citrate down, and Ranitidine HCL base and bismuth citrate are reacted, temperature of reaction is 0～35 ℃, reaction time is carried out the ultrasonic wave catalytic treatment to material to be made and reacts completely in 0.5～10 hour, isolated the bismuth ranitidine-citrate that is generated then from material.
2, the method for preparing bismuth ranitidine-citrate according to claim 1 is characterized in that, temperature of reaction is a room temperature.
3, the method for preparing bismuth ranitidine-citrate according to claim 2 is characterized in that, temperature of reaction is 18～28 ℃.
4, the method for preparing bismuth ranitidine-citrate according to claim 1 is characterized in that, the reaction times is 1～8 hour.
5, the method for preparing bismuth ranitidine-citrate according to claim 4 is characterized in that, the reaction times is 2.5～4 hours.
6, the method for preparing bismuth ranitidine-citrate according to claim 1 is characterized in that, the concentration of Diluted Alcohol is 5～20%, and used frequency of ultrasonic is to make material produce the frequency of resonance.
7, the method for preparing bismuth ranitidine-citrate according to claim 6 is characterized in that, used ultrasonic frequency is 30～50KHz.
8, according to the described method for preparing bismuth ranitidine-citrate of one of claim 1 to 6, it is characterized in that, the method of isolating the bismuth ranitidine-citrate that is generated from material is, with the material filtering after reacting completely, under violent stirring, add dewatering agent in the filtrate, make filtrate separate out throw out, after throw out filtration, drying, promptly get bismuth ranitidine-citrate.
9, the method for preparing bismuth ranitidine-citrate according to claim 8 is characterized in that, violent stirring is that agitator speed is the stirring that per minute 200～350 changes.
10, the method for preparing bismuth ranitidine-citrate according to claim 8 is characterized in that, the bismuth ranitidine-citrate of gained is the double salt that contains a crystal water, and its chemical formula is C
13H
22N
4O
3S1.1C
6H
5BiO
70.3C
2H
5OHH
2O.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99114171A CN1102585C (en) | 1999-04-28 | 1999-04-28 | Process for preparing bismuth ranitidine-citrate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99114171A CN1102585C (en) | 1999-04-28 | 1999-04-28 | Process for preparing bismuth ranitidine-citrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1236779A true CN1236779A (en) | 1999-12-01 |
| CN1102585C CN1102585C (en) | 2003-03-05 |
Family
ID=5277283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99114171A Expired - Lifetime CN1102585C (en) | 1999-04-28 | 1999-04-28 | Process for preparing bismuth ranitidine-citrate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1102585C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100364952C (en) * | 2005-12-23 | 2008-01-30 | 华东师范大学 | Process for hydrothermal synthesizing bismuth citrate |
| CN102304107A (en) * | 2011-07-13 | 2012-01-04 | 王健祥 | Method for preparing ranitidine carboxylic acid bismuth |
| CN102408398A (en) * | 2011-09-20 | 2012-04-11 | 江苏汉斯通药业有限公司 | Preparation method of ranitidine bismuth citrate |
| CN103896888A (en) * | 2014-03-28 | 2014-07-02 | 常州兰陵制药有限公司 | Preparation method of ranitidine bismuth citrate |
| CN107382921A (en) * | 2017-07-28 | 2017-11-24 | 常州兰陵制药有限公司 | The method for preparing bismuth citrate ranitidine |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100402514C (en) * | 2006-08-01 | 2008-07-16 | 丽珠医药集团股份有限公司 | Method of preparing bismuth citrate ranitidine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH679582A5 (en) * | 1988-07-18 | 1992-03-13 | Glaxo Group Ltd | |
| AU641903B2 (en) * | 1988-10-26 | 1993-10-07 | Glaxo Group Limited | Carboxylic acid derivatives |
| CN1156143A (en) * | 1995-10-20 | 1997-08-06 | 糜志远 | Preparing technology for bismuth citrate ranitidine product |
-
1999
- 1999-04-28 CN CN99114171A patent/CN1102585C/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100364952C (en) * | 2005-12-23 | 2008-01-30 | 华东师范大学 | Process for hydrothermal synthesizing bismuth citrate |
| CN102304107A (en) * | 2011-07-13 | 2012-01-04 | 王健祥 | Method for preparing ranitidine carboxylic acid bismuth |
| CN102408398A (en) * | 2011-09-20 | 2012-04-11 | 江苏汉斯通药业有限公司 | Preparation method of ranitidine bismuth citrate |
| CN103896888A (en) * | 2014-03-28 | 2014-07-02 | 常州兰陵制药有限公司 | Preparation method of ranitidine bismuth citrate |
| CN103896888B (en) * | 2014-03-28 | 2015-11-18 | 常州兰陵制药有限公司 | The preparation method of bismuth citrate ranitidine |
| CN107382921A (en) * | 2017-07-28 | 2017-11-24 | 常州兰陵制药有限公司 | The method for preparing bismuth citrate ranitidine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1102585C (en) | 2003-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108969770B (en) | Dipeptide modified 1-methyl-3-hydroxymethyl-tetrahydro-beta-carboline, synthesis and application thereof | |
| CN114315534A (en) | Preparation method of dapagliflozin intermediate | |
| CN1102585C (en) | Process for preparing bismuth ranitidine-citrate | |
| CN114249694A (en) | Preparation method of texas intermediate | |
| CN114621149B (en) | Method for synthesizing indazole compound by MOF-H248 catalysis | |
| CN1578769A (en) | Processes for the manufacturing of 3-hydroxy-n,1,6-trialkyl-4-oxo-1,4-dihydropyridine-2-carboxamide | |
| RU2074172C1 (en) | N-BENZYL-β-PHENYLISOSERIN-(2R,3S), METHOD FOR ITS PRODUCTION AND METHOD OF PRODUCTION OF ESTER OF b-PHENYLISOSERIN-(2R,3S) | |
| CN1297885A (en) | Preparation of 1.1-cyclohexyl oxalic amide | |
| CN112079823B (en) | Near-infrared frequency up-conversion fluorescence molecular probe, preparation method and application | |
| RU2334748C2 (en) | Method of production of 7-ethyl-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin | |
| RU2708243C1 (en) | Method of producing a phenylalanine compound | |
| CN113061111A (en) | Method for preparing amino acid compound with photocrosslinking activity | |
| CN1061349C (en) | Process for preparing loracarbff monohydrate | |
| RU2225866C1 (en) | Acetic acid potassium salt eliciting cardiotonic activity | |
| CN115197119B (en) | Preparation method of 6,6-dimethyl-3-azabicyclo [3.1.0] hexane-2, 4-dione | |
| CN110256387B (en) | Preparation method of medical intermediate | |
| CN109970822B (en) | Preparation method for synthesizing emamectin benzoate intermediate | |
| CN113861127B (en) | Preparation method of benzothiazole derivative drug molecules | |
| RU2248353C2 (en) | Method for preparing 3-methyl-1,2,4-triazolyl-5-thioacetate morpholinium | |
| US5041566A (en) | Method of preparing levoglucosenone | |
| RU2237662C1 (en) | Method for preparing 1-acetyl-2-imidazolidone | |
| RU2144534C1 (en) | Method of preparing morpholinium 3-methyl-1,2,4-triazolyl-5-thioacetate exhibiting hepato-protective, wound-healing, and antiviral activities | |
| SU690002A1 (en) | Method of preparing 4-methoxy-1,2-naphthoquinone | |
| SU1077883A1 (en) | Process for preparing beta-chloroethylsulfochloride | |
| SU1541211A1 (en) | Method of producing tetratozyl salt of meso-tetraoxy-(n-methyl-4-pyridyl)-porphirine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 213022 No. 352 labour East Road, Changzhou, Jiangsu Patentee after: CHANGZHOU LANLING PHARMACEUTICAL CO., LTD. Patentee after: Jiangsu Provincial Institute of Materia Medica Address before: 213011 No. 131, Qishuyan Avenue, Changzhou, Jiangsu Patentee before: CHANGZHOU LANLING PHARMACEUTICAL CO., LTD. Patentee before: Jiangsu Provincial Institute of Materia Medica |
|
| PP01 | Preservation of patent right |
Effective date of registration: 20160308 Granted publication date: 20030305 |
|
| RINS | Preservation of patent right or utility model and its discharge | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20160908 Granted publication date: 20030305 |
|
| RINS | Preservation of patent right or utility model and its discharge | ||
| CX01 | Expiry of patent term |
Granted publication date: 20030305 |
|
| CX01 | Expiry of patent term |